Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia

Neurobiology of Aging

Volumn 33, Issue 7, 2012, Pages 1345-1355

  Ashby, Emma L ^a   Love, Seth ^b   Kehoe, Patrick G ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Bradykinin; Kallikrein kinin system; Plasma kallikrein; Vascular dementia

Indexed keywords

KALLIKREIN; KININ; MESSENGER RNA; NEURON SPECIFIC ENOLASE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CADAVER; CELL LOSS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIINFARCT DEMENTIA; NERVE CELL; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TEMPORAL CORTEX; TREND STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRADYKININ; COHORT STUDIES; DEMENTIA, VASCULAR; FEMALE; FRONTAL LOBE; HUMANS; KALLIKREIN-KININ SYSTEM; KALLIKREINS; MALE; MIDDLE AGED; TEMPORAL LOBE;

EID: 84861202730     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.09.024     Document Type: Article

References (57)

1. Bartus R.T., Elliott P., Hayward N., Dean R., McEwen E.L., Fisher S.K. Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. J. Immunopharmacol 1996, 33:270-278.
2. Bennett S.A., Pappas B.A., Stevens W.D., Davidson C.M., Fortin T., Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol. Aging 2000, 21:207-214.
3. Bergamaschini L., Donarini C., Foddi C., Gobbo G., Parnetti L., Agostoni A. The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol Aging 2001, 22:63-69.
4. Bergamaschini L., Donarini C., Gobbo G., Parnetti L., Gallai V. Activation of complement and contact system in Alzheimer's disease. Mech. Ageing Dev 2001, 122:1971-1983.
5. Bergamaschini L., Parnetti L., Pareyson D., Canziani S., Cugno M., Agostoni A. Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord 1998, 12:102-108.
6. Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. Eur. Neurol 1993, 33:403-408.
7. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 2000, 21:153-160.
8. Bryant J.W., Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc. Hematol. Agents Med. Chem 2009, 7:234-250.
9. Buee L., Hof P.R., Bouras C., Delacourte A., Perl D.P., Morrison J.H., Fillit H.M. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol 1994, 87:469-480.
10. Bustin S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J. Mol. Endocrinol 2002, 29:23-39.
11. Butt A.M. Effect of inflammatory agents on electrical resistance across the blood-brain barrier in pial microvessels of anaesthetized rats. Brain Res 1995, 696:145-150.
12. Cerf M.E., Raidoo D.M. Immunolocalization of plasma kallikrein in human brain. Metab. Brain Dis 2000, 15:315-323.
13. DeKosky S.T., Shih W.J., Schmitt F.A., Coupal J., Kirkpatrick C. Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease: correlation with cognitive severity. Alzheimer Dis. Assoc. Disord 1990, 4:14-23.
14. DiScipio R.G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982, 45:587-595.
15. Eberling J.L., Jagust W.J., Reed B.R., Baker M.G. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol. Aging 1992, 13:483-491.
16. Farrall A.J., Wardlaw J.M. Blood-brain barrier: ageing and microvascular disease - systematic review and meta-analysis. Neurobiol. Aging 2009, 30:337-352.
17. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
18. Fink E., Bhoola K.D., Snyman C., Neth P., Figueroa C.D. Cellular expression of plasma prekallikrein in human tissues. Biol. Chem 2007, 388:957-963.
19. Fraser T., Tayler H., Love S. Low-temperature improved-throughput method for analysis of brain fatty acids and assessment of their postmortem stability. J. Neurosci. Methods 2008, 169:135-140.
20. Fujikawa K., Heimark R.L., Kurachi K., Davie E.W. Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry 1980, 19:1322-1330.
21. Gorlach C., Wahl M. Bradykinin dilates rat middle cerebral artery and its large branches via endothelial B2 receptors and release of nitric oxide. Peptides 1996, 17:1373-1378.
22. Hall E.D., Oostveen J.A., Dunn E., Carter D.B. Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp. Neurol 1995, 135:17-27.
23. Herholz K. PET studies in dementia. Ann. Nucl. Med 2003, 17:79-89.
24. Hirao K., Ohnishi T., Hirata Y., Yamashita F., Mori T., Moriguchi Y., Matsuda H., Nemoto K., Imabayashi E., Yamada M., Iwamoto T., Arima K., Asada T. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005, 28:1014-1021.
25. Ichinose A., Fujikawa K., Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem 1986, 261:3486-3489.
26. Imran M.B., Kawashima R., Awata S., Sato K., Kinomura S., Ono S., Sato M., Fukuda H. Tc-99m HMPAO SPECT in the evaluation of Alzheimer's disease: correlation between neuropsychiatric evaluation and CBF images. J. Neurol. Neurosurg. Psychiatry 1999, 66:228-232.
27. Iores-Marcal L.M., Viel T.A., Buck H.S., Nunes V.A., Gozzo A.J., Cruz-Silva I., Miranda A., Shimamoto K., Ura N., Araujo M.S. Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease. Peptides 2006, 27:3363-3369.
28. Johnson K.A., Jones K., Holman B.L., Becker J.A., Spiers P.A., Satlin A., Albert M.S. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998, 50:1563-1571.
29. Kalaria R.N., Maestre G.E., Arizaga R., Friedland R.P., Galasko D., Hall K., Luchsinger J.A., Ogunniyi A., Perry E.K., Potocnik F., Prince M., Stewart R., Wimo A., Zhang Z.X., Antuono P. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008, 7:812-826.
30. Komatani A., Yamaguchi K., Sugai Y., Takanashi T., Kera M., Shinohara M., Kawakatsu S. Assessment of demented patients by dynamic SPECT of inhaled xenon-133. J. Nucl. Med 1988, 29:1621-1626.
31. Kudo T., Imaizumi K., Tanimukai H., Katayama T., Sato N., Nakamura Y., Tanaka T., Kashiwagi Y., Jinno Y., Tohyama M., Takeda M. Are cerebrovascular factors involved in Alzheimer's disease?. Neurobiol. Aging 2000, 21:215-224.
32. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-δδ C(T)) method. Methods 2001, 25:402-408.
33. Mackic J.B., Stins M., Jovanovic S., Kim K.S., Bartus R.T., Zlokovic B.V. Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. Pharmacol. Res 1999, 16:1360-1365.
34. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
35. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci 2005, 99:6-38.
36. Neth P., Arnhold M., Nitschko H., Fink E. The mRNAs of prekallikrein, factors XI and XII, and kininogen, components of the contact phase cascade are differentially expressed in multiple non-hepatic human tissues. Thromb. Haemost 2001, 85:1043-1047.
37. Nishimura T., Hashikawa K., Fukuyama H., Kubota T., Kitamura S., Matsuda H., Hanyu H., Nabatame H., Oku N., Tanabe H., Kuwabara Y., Jinnouchi S., Kubol A. Decreased cerebral blood flow and prognosis of Alzheimer's disease: a multicenter HMPAO-SPECT study. Ann. Nucl. Med 2007, 21:15-23.
38. Niwa K., Kazama K., Younkin L., Younkin S.G., Carlson G.A., Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol 2002, 283:H315-H323.
39. Niwa K., Kazama K., Younkin S.G., Carlson G.A., Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis 2002, 9:61-68.
40. Onoue H., Kaito N., Tomii M., Tokudome S., Nakajima M., Abe T. Human basilar and middle cerebral arteries exhibit endothelium-dependent responses to peptides. Am. J. Physiol 1994, 267:H880-H886.
41. Raymond J.J., Robertson D.M., Dinsdale H.B. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can. J. Neurol. Sci 1986, 13:214-220.
42. Revesz T., Ghiso J., Lashley T., Plant G., Rostagno A., Frangione B., Holton J.L. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J. Neuropathol. Exp. Neurol 2003, 62:885-898.
43. Rombouts S.A., Goekoop R., Stam C.J., Barkhof F., Scheltens P. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. Neuroimage 2005, 26:1078-1085.
44. Schmaier A.H. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int. Immunopharmacol 2008, 8:161-165.
45. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med 2008, 14:837-842.
46. Shibayama Y., Joseph K., Nakazawa Y., Ghebreihiwet B., Peerschke E.I., Kaplan A.P. Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin. Immunol 1999, 90:89-99.
47. Tatton W.G., Chalmers-Redman R.M., Elstner M., Leesch W., Jagodzinski F.B., Stupak D.P., Sugrue M.M., Tatton N.A. Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J. Neural Transm. Suppl 2000, 60:77-100.
48. Tohgi H., Yonezawa H., Takahashi S., Sato N., Kato E., Kudo M., Hatano K., Sasaki T. Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology 1998, 40:131-137.
49. Unterberg A., Wahl M., Baethmann A. Effects of bradykinin on permeability and diameter of pial vessels in vivo. J. Cereb. Blood Flow Metab 1984, 4:574-585.
50. van Helmond Z., Heesom K., Love S. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. J. Neurosci. Methods 2009, 176:206-212.
51. Veerhuis R., Janssen I., Hoozemans J.J., De Groot C.J., Hack C.E., Eikelenboom P. Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathol 1998, 96:287-296.
52. Walker D.G., Yasuhara O., Patston P.A., McGeer E.G., McGeer P.L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res 1995, 675:75-82.
53. Whalley E.T., Amure Y.O., Lye R.H. Analysis of the mechanism of action of bradykinin on human basilar artery in vitro. Naunyn Schmiedebergs Arch. Pharmacol 1987, 335:433-437.
54. Wirth K.J., Fink E., Rudolphi K., Heitsch H., Deutschlander N., Wiemer G. Amyloid beta-(1-40) stimulates cyclic GMP production via release of kinins in primary cultured endothelial cells. Eur. J. Pharmacol 1999, 382:27-33.
55. Yasuhara O., Walker D.G., McGeer P.L. Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease. Brain Res 1994, 654:234-240.
56. Yong T., Linthicum D.S. Microvascular leakage in mouse pial venules induced by bradykinin. Brain Inj 1996, 10:385-393.
57. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005, 28:202-208.